<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/0WF6-GX40" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method GTA-7: Hepatocyte Primary ROS Assay</p><p><b>Protocol Abbreviation:</b> GTA-7</p><p><b>Protocol Version:</b> 1.1<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/0WF6-GX40>http://dx.doi.org/10.17917/0WF6-GX40</a></p><p><b>Protocol File:</b> protocols/20240410_18-35-01-023_NCL_Method_GTA-7.pdf<p><b>File Title:</b> GTA-7</p><p><b>Description:</b></b> This protocol describes the testing of nanoparticle formulations for reactive oxygen species (ROS) generation in male Sprague-Dawley (SD) primary hepatocytes, as part of the in vitro NCL preclinical characterization cascade.  The protocol utilizes a fluorescent redox active probe.  Primary hepatocytes were chosen since they have a greater metabolic activity than hepatocyte cell lines.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>